Daniel Sitar

Title: The Innovative Contributions of Daniel Sitar

Introduction

Daniel Sitar is a notable inventor based in Richmond, CA, who has made significant strides in the field of cancer detection. With a total of 2 patents, his work focuses on developing innovative methods for diagnosing lung cancer through biomarker panels.

Latest Patents

One of Sitar's latest patents is a method of detecting lung cancer using a biomarker panel for a urine test. This test detects biomarkers selected from a group that includes DMA, C5:1, C10:1, ADMA, C5-OH, SDMA, and kynurenine, or a combination thereof. Additionally, he has developed a serum test that detects biomarkers such as valine, arginine, ornithine, methionine, spermidine, spermine, diacetylspermine, C10:2, PC aa C32:2, PC ae C36:0, and PC ae C44:5; along with lysoPC a C18:2, or a combination thereof. Another significant patent involves a method for assaying the activity of the enzyme spermidine/spermine N-acetyltransferase (SSAT). This method utilizes SSAT substrates by detecting their acetylated forms, which may include rimantadine and tocainide, with their metabolism occurring partly through the action of the inducible enzyme SSAT.

Career Highlights

Throughout his career, Daniel Sitar has worked with various companies, including Biomark Cancer Systems Inc. and Biomark Technologies, Inc. His contributions to these organizations have been pivotal in advancing cancer detection technologies.

Collaborations

Sitar has collaborated with notable professionals in his field, including Rashid Bux and Brian K Cheng. Their combined expertise has further enhanced the development of innovative solutions in cancer diagnostics.

Conclusion

Daniel Sitar's work exemplifies the impact of innovation in medical technology, particularly in the early detection of lung cancer. His patents and collaborations reflect a commitment to improving healthcare outcomes through scientific advancements.